METHOD FOR PREDICTING EARLY ONSET AND SEVERITY OF LEVODOPA INDUCED DYSKINESIA (LID) IN SUBJECTS DIAGNOSED OF PARKINSON DISEASE (PD)

• 1. 一种预测急性胰腺炎患者严重程度的早期预测系统 [P] . 中国专利： CN114023433A . 2022-02-08
• 2. 帕金森病步态运动障碍严重程度的评估方法、系统及设备 [P] . 中国专利： CN111382679A . 2020-07-07
• 3. Nurr1 as a genetic target for treating levodopa-induced dyskinesias in Parkinson's disease [P] . 美国专利： US10144932B2 . 2018-12-04

  机译： Nurr1作为治疗左旋多巴诱发的帕金森氏病运动障碍的遗传靶标

• 4. NURR1 AS A GENETIC TARGET FOR TREATING LEVODOPA-INDUCED DYSKINESIAS IN PARKINSON'S DISEASE [P] . 美国专利： US2017198295A1 . 2017-07-13

  机译： NURR1作为治疗帕金森病中左多巴诱发的运动障碍的遗传学靶标

• 5. NURR1 AS A GENETIC TARGET FOR TREATING LEVODOPA-INDUCED DYSKINESIAS IN PARKINSON'S DISEASE [P] . 世界知识产权组织专利： WO2015188077A1 . 2015-12-10

  机译： NURR1作为治疗帕金森病中左多巴诱发的运动障碍的遗传学靶标

• 1. Compound Formula Rehmannia alleviates levodopa-induced dyskinesia in Parkinson’s disease [J] . Long Teng, Fang Hong, Chenguang Zhang, 中国神经再生研究（英文版） . 2014,第004期
• 2. The role of nerve growth factor inducible protein B in the pathogenesis of levodopa-induced dyskinesias [J] . 生物医学研究杂志（英文版） . 2006,第002期
• 3. Detection and assessment of the severity of levodopa-induced dyskinesia in patients with Parkinson's disease by neural networks. [J] . Keijsers NL, Horstink MW, van-Hilten JJ, Movement disorders . 2000,第6期
• 4. Presynaptic dopamine depletion determines the timing of levodopa-induced dyskinesia onset in Parkinson's disease [J] . Yoo Han Soo, Chung Seok Jong, Chung Su Jin, European Journal of Nuclear Medicine and Molecular Imaging . 2018,第3期
• 5. BDNF val66met influences time to onset of levodopa induced dyskinesia in Parkinson's disease. [J] . Foltynie T, Cheeran B, Williams-Gray CH, Journal of Neurology, Neurosurgery and Psychiatry . 2009,第2期
• 6. Validation of a New Model-Free Signal Processing Method for Gait Feature Extraction Using Inertial Measurement Units to Diagnose and Quantify the Severity of Parkinson's Disease [C] . Ali Akbari, Richard B. Dewey, Roozbeh Jafari International Conference on Computer Communication and Networks . 2017
• 7. Objective Vision-Based Assessment of Parkinsonism and Levodopa-Induced Dyskinesia in Persons with Parkinson's Disease. [D] . Li, Michael. 2017
• 8. Rapid drug increase and early onset of levodopa-induced dyskinesia in Parkinson’s disease [O] . Jin Yong Hong, Mun Kyung Sunwoo, Jung Han Yoon, 2020
• 9. PND22 Burden of L-Dopa-Induced Dyskinesia in Parkinson’s Disease Patients (PD-LID) in France – the Lidia Study Economic Analysis (Levodopa Induced Dyskinesia Impact Evaluation) [O] . Kryskowiak P., Viallet F., Brefel-Courbon C., 2013

• 1. Levodopa/Carbidopa Intestinal Gel for Treatment of Advanced Parkinson’s Disease: An Update on the Effects of Cognitive Functions [J] . Pamela Latino ,Stefania Tagliente ,Clelia Pellicano . 帕金森（英文） . 2017,第1期
• 2. Levodopa Pharmacokinetics in Brain after Both Oral and Intravenous Levodopa in One Patient with Advanced Parkinson’s Disease [J] . Maria Nord ,Peter Zsigmond ,Anita Kullman . 帕金森（英文） . 2017,第2期
• 3. Implementation and Validation of a Stride Length Estimation Algorithm,Using a Single Basic Inertial Sensor on Healthy Subjects and Patients Suffering from Parkinson’s Disease [J] . Benoit Sijobert ,Mourad Benoussaad ,Jennifer Denys . 健康（英文） . 2015,第6期
• 4. 老年帕金森病患者左旋多巴诱发运动障碍发生率及相关性因素分析 [C] . 李淑华 ,苏闻 ,曾湘豫 . 2015北京医学会神经病学学术年会 . 2015
• 5. 药源性运动障碍—左旋多巴诱发的异动症、盐酸苯海索引起的口舌咀嚼综合征、抗精神病药引起迟发性运动障碍与多巴胺D2受体基因多态性相关性研究 [A] . 李晓颖 . 2007